Taken together, our results suggest that additional (or higher) vaccine doses should be particularly encouraged for individuals at risk of lower anti-S1 responses to vaccination, including older individuals and those with obesity, diabetes, and/or COPD27–29. This evidence concerns the gene PSMD1 and obesity disorder.